Immutep Inc. (NASDAQ: IMMP) stock plunged by 3.51% at the last trading close whereas the IMMP stock gains by 5.96% in the premarket trading. Immutep has been setting the bar for the production of therapeutics that control Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that regulates T cells. Immutep Limited is a cutting-edge biotechnology firm focused on the development of novel immunotherapy drugs for diseases like cancer, infectious disease, and autoimmune disease.
Overview of LAG-3 research
The LAG-3 protein regulates contact among T cells and antigen-presenting cells (APCs), which are necessary for the adaptive immune response. Dr. Frederic Triebel, Immutep’s Chief Scientific Officer and Chief Medical Officer, not only leads the way with his LAG-3 research, but he also sets the research standard. Immutep has risen to the top of the global immunotherapy drug market for cancer and autoimmune diseases as a result of this research.
The CEO of Immutep Marc Voigt said that they are a LAG-3 firm and have more LAG-3-related systems than anyone else, even in the pharmaceutical industry. In fact, no new, accepted, or validated checkpoint has been established in the last six years. LAG-3 is their chance to be the next big thing in vaccine growth.
Immutep’s goal is to use clinical intervention to activate and improve the body’s own immune system for the benefit of patients’ wellbeing, similar to how immunotherapy battles cancer and autoimmune diseases.
Other Recent Development
Through a pharmaceutical collaboration of IMMP with Novartis and GlaxoSmithKline, IMMP now has one preclinical and three clinical LAG-3 product candidates under production, plus two antibodies for activating immune responses in autoimmunity and cancer. The proposed 160-patient TACTI-003 trial relies on the successful Phase 2 TACTI-002 results (also with MSD), which indicated a doubling of the overall response rate with ei-pembro in usually unresponsive PD-1 and PD-L1 2nd-line HNSCC patients, including three full responses, as well as promising data in 1st- and 2nd-line NSCLC patients.
